SHP2 phosphatase as a novel therapeutic target for melanoma treatment

Ruo Yu Zhang, Zhi Hong Yu, Lifan Zeng, Sheng Zhang, Yunpeng Bai, Jinmin Miao, Lan Chen, Jingwu Xie, Zhong-Yin Zhang

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Melanoma ranks among the most aggressive and deadly human cancers. Although a number of targeted therapies are available, they are effective only in a subset of patients and the emergence of drug resistance often reduces durable responses. Thus there is an urgent need to identify new therapeutic targets and develop more potent pharmacological agents for melanoma treatment. Herein we report that SHP2 levels are frequently elevated in melanoma, and high SHP2 expression is significantly associated with more metastatic phenotype and poorer prognosis. We show that SHP2 promotes melanoma cell viability, motility, and anchorage-independent growth, through activation of both ERK1/2 and AKT signaling pathways. We demonstrate that SHP2 inhibitor 11a-1 effectively blocks SHP2-mediated ERK1/2 and AKT activation and attenuates melanoma cell viability, migration and colony formation. Most importantly, SHP2 inhibitor 11a-1 suppresses xenografted melanoma tumor growth, as a result of reduced tumor cell proliferation and enhanced tumor cell apoptosis. Taken together, our data reveal SHP2 as a novel target for melanoma and suggest SHP2 inhibitors as potential novel therapeutic agents for melanoma treatment.

Original languageEnglish (US)
Pages (from-to)73817-73829
Number of pages13
JournalOncotarget
Volume7
Issue number45
DOIs
StatePublished - 2016

Fingerprint

Non-Receptor Type 11 Protein Tyrosine Phosphatase
Melanoma
Therapeutics
Cell Movement
Neoplasms
Cell Survival
Growth
Drug Resistance
Cell Proliferation
Pharmacology
Apoptosis
Phenotype

Keywords

  • Drug discovery
  • Melanoma
  • Protein tyrosine phosphatase
  • SHP2
  • SHP2 inhibitor

ASJC Scopus subject areas

  • Oncology

Cite this

Zhang, R. Y., Yu, Z. H., Zeng, L., Zhang, S., Bai, Y., Miao, J., ... Zhang, Z-Y. (2016). SHP2 phosphatase as a novel therapeutic target for melanoma treatment. Oncotarget, 7(45), 73817-73829. https://doi.org/10.18632/oncotarget.12074

SHP2 phosphatase as a novel therapeutic target for melanoma treatment. / Zhang, Ruo Yu; Yu, Zhi Hong; Zeng, Lifan; Zhang, Sheng; Bai, Yunpeng; Miao, Jinmin; Chen, Lan; Xie, Jingwu; Zhang, Zhong-Yin.

In: Oncotarget, Vol. 7, No. 45, 2016, p. 73817-73829.

Research output: Contribution to journalArticle

Zhang, RY, Yu, ZH, Zeng, L, Zhang, S, Bai, Y, Miao, J, Chen, L, Xie, J & Zhang, Z-Y 2016, 'SHP2 phosphatase as a novel therapeutic target for melanoma treatment', Oncotarget, vol. 7, no. 45, pp. 73817-73829. https://doi.org/10.18632/oncotarget.12074
Zhang RY, Yu ZH, Zeng L, Zhang S, Bai Y, Miao J et al. SHP2 phosphatase as a novel therapeutic target for melanoma treatment. Oncotarget. 2016;7(45):73817-73829. https://doi.org/10.18632/oncotarget.12074
Zhang, Ruo Yu ; Yu, Zhi Hong ; Zeng, Lifan ; Zhang, Sheng ; Bai, Yunpeng ; Miao, Jinmin ; Chen, Lan ; Xie, Jingwu ; Zhang, Zhong-Yin. / SHP2 phosphatase as a novel therapeutic target for melanoma treatment. In: Oncotarget. 2016 ; Vol. 7, No. 45. pp. 73817-73829.
@article{d1ec57c3dfa64191b0ca7cd36342b08d,
title = "SHP2 phosphatase as a novel therapeutic target for melanoma treatment",
abstract = "Melanoma ranks among the most aggressive and deadly human cancers. Although a number of targeted therapies are available, they are effective only in a subset of patients and the emergence of drug resistance often reduces durable responses. Thus there is an urgent need to identify new therapeutic targets and develop more potent pharmacological agents for melanoma treatment. Herein we report that SHP2 levels are frequently elevated in melanoma, and high SHP2 expression is significantly associated with more metastatic phenotype and poorer prognosis. We show that SHP2 promotes melanoma cell viability, motility, and anchorage-independent growth, through activation of both ERK1/2 and AKT signaling pathways. We demonstrate that SHP2 inhibitor 11a-1 effectively blocks SHP2-mediated ERK1/2 and AKT activation and attenuates melanoma cell viability, migration and colony formation. Most importantly, SHP2 inhibitor 11a-1 suppresses xenografted melanoma tumor growth, as a result of reduced tumor cell proliferation and enhanced tumor cell apoptosis. Taken together, our data reveal SHP2 as a novel target for melanoma and suggest SHP2 inhibitors as potential novel therapeutic agents for melanoma treatment.",
keywords = "Drug discovery, Melanoma, Protein tyrosine phosphatase, SHP2, SHP2 inhibitor",
author = "Zhang, {Ruo Yu} and Yu, {Zhi Hong} and Lifan Zeng and Sheng Zhang and Yunpeng Bai and Jinmin Miao and Lan Chen and Jingwu Xie and Zhong-Yin Zhang",
year = "2016",
doi = "10.18632/oncotarget.12074",
language = "English (US)",
volume = "7",
pages = "73817--73829",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "45",

}

TY - JOUR

T1 - SHP2 phosphatase as a novel therapeutic target for melanoma treatment

AU - Zhang, Ruo Yu

AU - Yu, Zhi Hong

AU - Zeng, Lifan

AU - Zhang, Sheng

AU - Bai, Yunpeng

AU - Miao, Jinmin

AU - Chen, Lan

AU - Xie, Jingwu

AU - Zhang, Zhong-Yin

PY - 2016

Y1 - 2016

N2 - Melanoma ranks among the most aggressive and deadly human cancers. Although a number of targeted therapies are available, they are effective only in a subset of patients and the emergence of drug resistance often reduces durable responses. Thus there is an urgent need to identify new therapeutic targets and develop more potent pharmacological agents for melanoma treatment. Herein we report that SHP2 levels are frequently elevated in melanoma, and high SHP2 expression is significantly associated with more metastatic phenotype and poorer prognosis. We show that SHP2 promotes melanoma cell viability, motility, and anchorage-independent growth, through activation of both ERK1/2 and AKT signaling pathways. We demonstrate that SHP2 inhibitor 11a-1 effectively blocks SHP2-mediated ERK1/2 and AKT activation and attenuates melanoma cell viability, migration and colony formation. Most importantly, SHP2 inhibitor 11a-1 suppresses xenografted melanoma tumor growth, as a result of reduced tumor cell proliferation and enhanced tumor cell apoptosis. Taken together, our data reveal SHP2 as a novel target for melanoma and suggest SHP2 inhibitors as potential novel therapeutic agents for melanoma treatment.

AB - Melanoma ranks among the most aggressive and deadly human cancers. Although a number of targeted therapies are available, they are effective only in a subset of patients and the emergence of drug resistance often reduces durable responses. Thus there is an urgent need to identify new therapeutic targets and develop more potent pharmacological agents for melanoma treatment. Herein we report that SHP2 levels are frequently elevated in melanoma, and high SHP2 expression is significantly associated with more metastatic phenotype and poorer prognosis. We show that SHP2 promotes melanoma cell viability, motility, and anchorage-independent growth, through activation of both ERK1/2 and AKT signaling pathways. We demonstrate that SHP2 inhibitor 11a-1 effectively blocks SHP2-mediated ERK1/2 and AKT activation and attenuates melanoma cell viability, migration and colony formation. Most importantly, SHP2 inhibitor 11a-1 suppresses xenografted melanoma tumor growth, as a result of reduced tumor cell proliferation and enhanced tumor cell apoptosis. Taken together, our data reveal SHP2 as a novel target for melanoma and suggest SHP2 inhibitors as potential novel therapeutic agents for melanoma treatment.

KW - Drug discovery

KW - Melanoma

KW - Protein tyrosine phosphatase

KW - SHP2

KW - SHP2 inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84995740074&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995740074&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.12074

DO - 10.18632/oncotarget.12074

M3 - Article

C2 - 27650545

AN - SCOPUS:84995740074

VL - 7

SP - 73817

EP - 73829

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 45

ER -